Ac alone or as tandem treatment for patients with end-stage cancer. Treatments were relatively well tolerated without serious adverse effects. 3BP-3940 FRT demonstrated favorable biodistribution (exceptionally very low renal accumulation), significant tumor uptake, and long retention with very high tumor-to-background ratios, demonstrating objective responses in advanced, aggressive, and heavily pretreated metastatic adenocarcinomas and sarcomas. The observed survival benefit appears to be highly promising. Further prospective randomized analysis in a larger cohort with longer follow-up is warranted.
Baum et al. (Mon,) studied this question.